Abstract

To better understand a role of eIF4E S209 in oncogenic translation, we generated EIF4ES209A/+ heterozygous knockin (4EKI) HCT 116 human colorectal cancer (CRC) cells. 4EKI had little on total eIF4E levels, cap binding or global translation, while markedly reduced HCT 116 cell growth in spheroids and mice, and CRC organoid growth. 4EKI strongly inhibited Myc and ATF4 translation, the integrated Stress Response (ISR)-dependent glutamine metabolic signature, AKT activation and proliferation in vivo. 4EKI inhibited polyposis in ApcMin/+ mice by suppressing Myc protein and AKT activation. Furthermore, p-eIF4E was highly elevated in CRC precursor lesions in mouse and human. p-eIF4E cooperated with mutant KRAS to promote Myc and ISR-dependent glutamine addiction in various CRC cell lines, characterized by increased cell death, transcriptomic heterogeneity and immune suppression upon deprivation. These findings demonstrate a critical role of eIF4E S209-dependent translation in Myc and stress-driven oncogenesis and as a potential therapeutic vulnerability.

Data availability

Microarray data is deposited in Dryad under doi:10.5061/dryad.tb2rbnzxm.All data generated or analyzed during this study are included in the manuscript and supporting files.

The following data sets were generated
    1. YU
    2. Jian
    (2020) Microarray data
    Dryad Digital Repository, doi:10.5061/dryad.tb2rbnzxm.

Article and author information

Author details

  1. Hang Ruan

    Pathology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  2. Xiangyun Li

    Pathology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  3. Xiang Xu

    Stem Cell and Regenerative Medicine, Daping Hospital, Chongqing, China
    Competing interests
    No competing interests declared.
  4. Brian J Leibowitz

    Pathology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  5. Jingshan Tong

    Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  6. Lujia Chen

    Medical Informatics, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  7. Luoquan Ao

    Stem Cell and Regenerative Medicine, Daping Hospital, Chongqing, China
    Competing interests
    No competing interests declared.
  8. Wei Xing

    Stem Cell and Regenerative Medicine, Daping Hospital, Chongqing, China
    Competing interests
    No competing interests declared.
  9. Jianhua Luo

    Pathology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  10. Yanping Yu

    Pathology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  11. Robert E Schoen

    Medicine, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  12. Nahum Sonenberg

    Goodman Cancer Research Center, McGill University, Montreal, Canada
    Competing interests
    Nahum Sonenberg, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4707-8759
  13. Xinghua Lu

    Biomedical Informatics, University of Pittsburgh, Pittsbrugh, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8599-2269
  14. Lin Zhang

    Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  15. Jian Yu

    Pathology, University of Pittsburgh, Pittsburgh, United States
    For correspondence
    yuj2@upmc.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4021-1000

Funding

NIH (R01CA215481)

  • Jian Yu

NIH (R01CA172136)

  • Lin Zhang

NIH (R01CA203028)

  • Lin Zhang

NIH (R01CA236271)

  • Lin Zhang

NIH (R01LM012011)

  • Xinghua Lu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Wafik S El-Deiry, Brown University, United States

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (# 19085635 and 18063020) of the University of Pittsburgh. All animal experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee under Animal welfare assurance number A-3187-01. No surgery or invasive procedure was performed and every effort was made to minimize suffering with humane sacrifice.

Version history

  1. Received: June 17, 2020
  2. Accepted: October 31, 2020
  3. Accepted Manuscript published: November 2, 2020 (version 1)
  4. Version of Record published: November 13, 2020 (version 2)

Copyright

© 2020, Ruan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,146
    views
  • 335
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Hang Ruan
  2. Xiangyun Li
  3. Xiang Xu
  4. Brian J Leibowitz
  5. Jingshan Tong
  6. Lujia Chen
  7. Luoquan Ao
  8. Wei Xing
  9. Jianhua Luo
  10. Yanping Yu
  11. Robert E Schoen
  12. Nahum Sonenberg
  13. Xinghua Lu
  14. Lin Zhang
  15. Jian Yu
(2020)
eIF4E S209 phosphorylation licenses Myc-and stress-driven oncogenesis
eLife 9:e60151.
https://doi.org/10.7554/eLife.60151

Share this article

https://doi.org/10.7554/eLife.60151

Further reading

    1. Cancer Biology
    2. Cell Biology
    Julian J A Hoving, Elizabeth Harford-Wright ... Alison C Lloyd
    Research Article

    Collective cell migration is fundamental for the development of organisms and in the adult, for tissue regeneration and in pathological conditions such as cancer. Migration as a coherent group requires the maintenance of cell-cell interactions, while contact inhibition of locomotion (CIL), a local repulsive force, can propel the group forward. Here we show that the cell-cell interaction molecule, N-cadherin, regulates both adhesion and repulsion processes during rat Schwann cell (SC) collective migration, which is required for peripheral nerve regeneration. However, distinct from its role in cell-cell adhesion, the repulsion process is independent of N-cadherin trans-homodimerisation and the associated adherens junction complex. Rather, the extracellular domain of N-cadherin is required to present the repulsive Slit2/Slit3 signal at the cell-surface. Inhibiting Slit2/Slit3 signalling inhibits CIL and subsequently collective Schwann cell migration, resulting in adherent, nonmigratory cell clusters. Moreover, analysis of ex vivo explants from mice following sciatic nerve injury showed that inhibition of Slit2 decreased Schwann cell collective migration and increased clustering of Schwann cells within the nerve bridge. These findings provide insight into how opposing signals can mediate collective cell migration and how CIL pathways are promising targets for inhibiting pathological cell migration.

    1. Cancer Biology
    2. Structural Biology and Molecular Biophysics
    Johannes Paladini, Annalena Maier ... Stephan Grzesiek
    Research Article

    Abelson tyrosine kinase (Abl) is regulated by the arrangement of its regulatory core, consisting sequentially of the SH3, SH2, and kinase (KD) domains, where an assembled or disassembled core corresponds to low or high kinase activity, respectively. It was recently established that binding of type II ATP site inhibitors, such as imatinib, generates a force from the KD N-lobe onto the SH3 domain and in consequence disassembles the core. Here, we demonstrate that the C-terminal αI-helix exerts an additional force toward the SH2 domain, which correlates both with kinase activity and type II inhibitor-induced disassembly. The αI-helix mutation E528K, which is responsible for the ABL1 malformation syndrome, strongly activates Abl by breaking a salt bridge with the KD C-lobe and thereby increasing the force onto the SH2 domain. In contrast, the allosteric inhibitor asciminib strongly reduces Abl’s activity by fixating the αI-helix and reducing the force onto the SH2 domain. These observations are explained by a simple mechanical model of Abl activation involving forces from the KD N-lobe and the αI-helix onto the KD/SH2SH3 interface.